Substance use disorder: Epidemiology, medical consequences and treatment. / Trastorno por uso de sustancias: epidemiología, complicaciones médicas y tratamiento.

Substance use is a common health problem, and substance use disorder, which is its most severe presentation, is associated with multiple medical consequences and a negative impact on individual and on population health. Substance use disorder needs to be addressed as any chronic medical condition; therefore, it has to be detected at the early stages and has to be properly treated to prevent drug-related harm. Internists should be able to recognize and treat intoxication and abstinence. Internists should also be able to refer the patient to state of the art long term treatment, aimed to detoxification and treatment induction to promote abstinence and prevent relapse. In this narrative review we will discuss substance use epidemiology, its main medical consequences and its treatment, with a focus on alcohol, opiates, cocaine and other stimulants, cannabis and benzodiazepines.

Efectividad del programa de mantenimiento con opioides para el tratamiento de su dependencia, en prisión / Effectiveness of opioid maintenance programs for treating drug dependence in prisons

Objetivos: Evaluar la efectividad del programa de mantenimiento con opioides en el tratamiento de su dependencia en prisiones españolas. Material y método: Se realizó una revisión bibliográfica narrativa en las siguientes bases de datos: PubMed, Cochrane, IBECS, LILACS y HealthCare. Se eligieron preferentemente todos aquellos ensayos clínicos, así como artículos de revisión sistemática y algún artículo que se consideró relevante por su contenido. El periodo de tiempo se limitó entre enero de 2011 y noviembre de 2021. El idioma de búsqueda fue: inglés, español y catalán. Se rechazaron los artículos repetidos y los que no tuvieron relación con los objetivos. Los criterios de búsqueda fueron: methadone AND prisons; opiate substitution treatment AND prisons; methadone AND buprenorphine; methadone OR buprenorphine; prisons AND Methadone AND buprenorphine. Resultados: Fueron seleccionados 20 artículos de 647 consultados, tras la aplicación de los filtros correspondientes y tras descartar los artículos duplicados. Discusión: Se evidenció una ligera mayor efectividad de la buprenorfina frente a la metadona. Se destacó una elevada prevalencia del programa, así como variedad de efectos adversos de la metadona. Su utilidad sobre el comportamiento obtiene disparidad de opiniones. Se anuncia la posibilidad de nuevas alternativas de tratamiento con un mejor control farmacológico. (AU)

Objectives: To evaluate the effectiveness of opioid maintenance programs in treating opioid dependence in Spanish prisons. Material and method: A narrative bibliographic review was carried out on the following databases: PubMed; Cochrane; IBECS; LILACS; HealthCare. All clinical trials were chosen as a preference, along with systematic review articles and some articles that were considered relevant for their content. The time period was limited to between January 2011 and November 2021. The languages chosen were English, Spanish and Catalan. Repeated articles and those that were not related to the objectives were rejected. The search criteria were: “methadone AND prisons”; “opiate substitution treatment AND prisons”; “methadone AND buprenorphine”; “methadone OR buprenorphine”; “prisons AND Methadone AND buprenorphine”. Results: 20 articles were selected out of 647 items consulted after applying the corresponding filters and after discarding duplicates. Discussion: There was a slightly greater effectiveness of buprenorphine versus methadone. The high prevalence of the program was highlighted, as well as the variety of adverse effects of methadone. Usefulness with regard to inmates’ behavior showed a range of opinions. The possibility of new treatment alternatives with better pharmacological control is mentioned. (AU)

Treatment of dissociative symptoms with opioid antagonists: a systematic review.

BACKGROUND: The clinical guidelines for the treatment of dissociation focus primarily on psychotherapy. However, different psychoactive drugs are used in clinical practice. The use of opioid antagonists has been proposed as a therapeutic option based on the theory that dissociation might be a phenomenon mediated by dysregulation of the endogenous opioid system. OBJECTIVE: To review and meta-analyse the available evidence on the efficacy of the opioid antagonists naltrexone, naloxone, and nalmefene as treatments for dissociative symptoms and disorders. METHOD: The PRISMA guidelines were followed, and this review was registered in Prospero with reference number CRD42021280976. The search was performed in the PubMed, Scopus, Web of Science, EMBASE, PsycINFO, and PubPsych databases. RESULTS: 1,798 citations were obtained. After removing duplicates and applying inclusion and exclusion criteria, we included 5 comparative studies with 9 dissociation measures that had included a total of 154 participants, of whom 134 had been treated with an opioid antagonist. The results of the meta-analysis showed a treatment effect for dissociation when using opioid antagonists [pooled d = 1.46 (95% CI: 0.62-2.31)]. However, the studies we included were very heterogeneous [Q = 66.89 (p < .001)] and there may have been publication bias. CONCLUSIONS: Although more research is needed and the results must be interpreted with caution because of the limited amount of data and heterogeneity in the studies and their methodological qualities, opioid antagonists (particularly naltrexone) are promising candidates for the treatment of dissociative symptoms and showed a moderate - large effect size in reducing these symptoms.

The results of the meta-analysis showed a treatment effect for dissociation when using opioid antagonists [pooled d = 1.46 (95% CI: 0.62­2.31)].The results must be interpreted with caution because of the limited amount of data and heterogeneity in the studies and their methodological qualities.Opioid antagonists (particularly naltrexone) are promising candidates for the treatment of dissociative symptoms and showed a moderate ­ large effect size in reducing these symptoms.

Amapola, lindísima amapola: de los opiáceos y los opioides, utilidad y riesgos / Poppy, beautiful poppy: opiates and opioids, utility and risks

Resumen El opio y sus derivados, y recientemente los opioides, han acompañado a la humanidad desde las civilizaciones más antiguas hasta la actualidad. Sus efectos analgésicos, hipnóticos y placenteros no pasaron desapercibidos para los antiguos, los consideraron de utilidad médica y beneficiosa para el estado de ánimo. Hoy en día no existe otro tipo de medicamentos que puedan tratar el dolor más intenso tan eficientemente como estos potentes analgésicos. Sin embargo, el uso médico y recreativo de los opiáceos y los opioides conlleva riesgos para la salud, como la tolerancia, la hiperalgesia y la adicción. Actualmente, además de ser indiscutiblemente el tratamiento médico más poderoso para mitigar el sufrimiento ocasionado por el dolor, se ha convertido también en un problema de salud pública debido a la alta cantidad de personas con trastorno por uso de opioides y por las muertes ocasionadas por sobredosis. En esta revisión se hará mención de las bondades de los opiáceos y opioides, y también de los efectos no deseados que estos producen.

Abstract Opium and its derivatives, and recently the opioids have accompanied the humankind since the ancient civilizations to the present day. Its analgesic, hypnotic and pleasant effects did not go unnoticed by ancient people, which considered most of these effects of medical utility and noticed that they had remarkable mood benefits. Currently, there are no other kind of drugs that can palliate intense pain as efficiently as these powerful analgesics. However, the medical and recreational use of opiates and opioids may carry health risks such as tolerance, hyperalgesia, and addiction. Nowadays, in addition to being indisputably the most powerful medical treatment to alleviate the suffering caused by pain, it has also become a public health problem due to the high number of people with opioid use disorder that have facilitated deaths caused by opioids overdose. In this review we will discuss the medical benefits of opiates and opioids, as much as the unwanted effects they produce.

Positivo a opiáceos en análisis de drogas de abuso en orina tras consumo de semillas de amapola. A propósito de un caso / Positive for opiates in urine drug of abuse test after poppy seed consumption. A case report

Antecedentes y objetivos: las semillas de amapola, cuyo consumo solas o contenidas en ciertos alimentos es considerado seguro en España desde el punto de vista toxicológico, presentan cierta cantidad de alcaloides opiáceos que pueden originar resultados «falsos positivos» en los análisis de drogas de abuso en muestras de orina, como los realizados de forma rutinaria, entre otros colectivos, al personal de las Fuerzas Armadas. A raíz de un caso detectado en el Instituto de Toxicología de la Defensa de resultado positivo a opiáceos en una persona que reportó el consumo de un pan con semillas de amapola, se propuso realizar un estudio de esta problemática y cómo abordarla desde el punto de vista analítico. Material y método: se estudió en dos voluntarios cómo afectó el consumo de dicho pan, analizándose muestras de orina, tanto por métodos de cribado como de confirmación, y se apoyó en una revisión bibliográfica empleando distintas bases de datos especializadas en referencia a la interferencia del consumo de semillas de amapola con las analíticas de drogas de abuso en muestras de orina. Resultados: aplicando el punto de corte de 300 ng/ml recomendado por la European Workplace Drug Testing Society (EWDTS) resultaron presuntamente positivos a opiáceos el 62,5% de los análisis de cribado. En ciertas muestras, el análisis de confirmación identificó codeína por encima del límite de detección establecido en la técnica analítica. La bibliografía apoyó estos resultados. Conclusiones: para abordar analíticamente esta problemática se ha propuesto incrementar, en la técnica analítica de confirmación, el punto de corte de confirmación y, asimismo, como otras posibles medidas a implementar se ha planteado la detección de tebaína como biomarcador específico del consumo de semillas de amapola y/o el incremento del punto de corte hasta los 2000 ng/ml. (AU)

Antecedents and objectives: Poppy seeds, whose consumption alone or contained in certain foods is considered safe in Spain from the toxicological point of view, have different amounts of opioid alkaloids that can cause «false positive» results in the analysis of drugs of abuse in urine samples, such as those routinely performed, among other groups, on Armed Forces personnel. Following a case detected at the Institute of Toxicology of the Defense of a positive result to opiates in a person who reported the consumption of a bread containing poppy seeds, it was proposed to carry out a study of this problem and how to approach it from the analytical point of view. Material and methods: We studied how the consumption of this bread affected to two volunteers, analyzing urine samples by both screening and confirmation methods, and was supported by a literature review using different specialized databases in reference to the interference of the consumption of poppy seeds and products containing them with the analysis of drugs of abuse in urine samples. Results: Using the 300 ng/ml cut-off point, 62% of the screening tests were presumably positive to opiates. In certain samples the confirmatory analysis identified codeine above the established detection limit. The literature supported these results. Conclusions: In order to deal with this problem analytically, it has been proposed to increase the confirmation cut-off level in the analytical confirmatory technique. In addition, the detection of thebaine as a specific biomarker for poppy seed consumption and/or the increase of the cut-off point to 2000 ng/ml has been proposed as other possible measures to be implemented. (AU)

Diferencias clínicas entre los pacientes con dolor crónico primario y secundario atendidos por una unidad multidisciplinar de dolor crónico infantil / Clinical differences in a multidisciplinary pediatric pain unit between primary and secondary chronic pain

Introducción: El dolor crónico afecta a un porcentaje significativo de la población pediátrica en los países desarrollados, y puede tener una causa médica bien definida en el dolor crónico secundario (DCS), o desconocida en el dolor crónico primario (DCP). En España, hasta el momento, no existe información acerca de las diferencias clínicas de los pacientes atendidos en unidades multidisciplinarias. Métodos: Análisis retrospectivo de las historias clínicas de los pacientes atendidos en 2018 por la Unidad de Dolor Crónico Infantil del Hospital Universitario La Paz. Resultados: Se incluyeron los 92 pacientes atendidos, con edades comprendidas entre 2 y 19 años, y una edad media de 12,4 (SD=4,1) años, mayoritariamente de sexo femenino (55%) y una duración media del dolor de 11,3 (SD=10,4) meses. Los resultados de comparar pacientes con DCP (n=31) y DCS (n=61) mostraron que ambos grupos presentaban dolor medio con una gran intensidad (x=5,9; SD=2,2; rango=0-10), con duración y repercusión funcional similares, aunque el DCP se asoció menos a descriptores de tipo neuropático que el DCS (p=0,040) y era más extenso en su localización (p<0,001). Ambos grupos recibieron similar tratamiento basado en rehabilitación, psicoterapia, técnicas invasivas y tratamiento con medicación analgésica, aunque los pacientes del grupo DCP recibieron menos medicaciones analgésicas (gabapentinoides y opiáceos) que el DCS (p=0,011). Conclusión: Los pacientes con DCP o DCS, aunque tengan un perfil clínico similar, presentan diferencias en el número y tipo de analgésicos empleados, lo que avalaría la importancia del diagnóstico de la causa para adecuar el tratamiento farmacológico subsiguiente.(AU)

Introduction: Chronic pain affects an important part of the pediatric population in developed countries. secondary chronic pain (SCP) can have a well-defined medical cause, but primary chronic pain (PCP) can have an unknown etiology. In Spain, there is as yet no information on the clinical differences between patients treated in multidisciplinary units. Methods: Retrospective analysis of the clinical records of patients seen in 2018 at the Children's Chronic Pain Unit in University La Paz Hospital. Results: A total of 92 patients were included (age between 3 and 19 years), with a mean age of 12.4 (SD=4.1) years, mostly female (55%), with a mean duration of pain of 11.3 (SD=10.4) months. A comparison of patients with PCP (n=31) and SCP (n=61) showed that both groups, on average, presented intense pain (X=5.9; SD=2.2; range=0-10), with similar duration and functional repercussions, although PCP was less likely to be associated with neuropathic descriptors than SCP (p=.040), and was more extensive (p<.001). Both groups received similar treatment, based on rehabilitation, psychotherapy, invasive techniques and analgesic medication, although patients in the PCP group received less analgesic medication (gabapentinoids and opioids) than the SCP (p=.011). Conclusion: Patients treated in a multidisciplinary Child Pain Unit for PCP or SCP present a very similar clinical profile, though with differences in the number and type of analgesic drugs used. This shows the importance of etiologic diagnosis for adequate pharmacological treatment.(AU)

Clinical differences in a multidisciplinary pediatric pain unit between primary and secondary chronic pain.

INTRODUCTION: Chronic pain affects an important part of the pediatric population in developed countries. secondary chronic pain (SCP) can have a well-defined medical cause, but primary chronic pain (PCP) can have an unknown etiology. In Spain, there is as yet no information on the clinical differences between patients treated in multidisciplinary units. METHODS: Retrospective analysis of the clinical records of patients seen in 2018 at the Children's Chronic Pain Unit in University La Paz Hospital. RESULTS: A total of 92 patients were included, (age between 3 and 19 years), with a mean age of 12.4 (SD = 4.1) years, mostly female (55%), with a mean duration of pain of 11.3 (SD = 10.4) months. A comparison of patients with PCP (n = 31) and SCP (n = 61) showed that both groups, on average, presented intense pain (X = 5.9; SD = 2.2; range = 0-10), with similar duration and functional repercussions, although PCP was less likely to be associated with neuropathic descriptors than SCP (p = 0.040), and was more extensive (p < 0.001). Both groups received similar treatment, based on rehabilitation, psychotherapy, invasive techniques and analgesic medication, although patients in the PCP group received less analgesic medication (gabapentinoids and opioids) than the SCP (p = 0.011). CONCLUSION: Patients treated in a multidisciplinary Child Pain Unit for PCP or SCP present a very similar clinical profile, though with differences in the number and type of analgesic drugs used. This shows the importance of etiologic diagnosis for adequate pharmacological treatment.

Relationship between optical coherence tomography findings and clinical variables in patients with opiate use disorder / Relação entre os achados da tomografia de coerência óptica e as variáveis clínicas em pacientes com transtorno por uso de opiáceos

ABSTRACT Purpose: This study aimed to examine optical coherence tomography findings in patients with opiate use disorder by comparing them with healthy controls. Methods: The study included 30 opiate use disorder patients and 30 controls. The participants' detailed biomicroscopic examinations, visual acuity, intraocular pressure, and both eye examinations were evaluated. A total of 120 eyes were evaluated using optical coherence tomography, measuring the central macular thickness, mean macular thickness, mean macular volume and retinal nerve fiber layer thickness. Moreover, all participants filled in the demographic data form and Barratt Impulsiveness Scale. Results: Upon examination of the optical coherence tomography findings, central macular thickness, mean macular thickness, and mean macular volume were thinner in both eyes in patients with opiate use disorder (p<0.01 in all measurements in both eyes). Similarly, the total values of the superior quadrant and retinal nerve fiber layer thickness were statistically significant in both eyes compared to that in the control group (p=0.007, p=0.002; p=0.049, p=0.007, in the right and left eyes, respectively). Only the left eye was positively correlated with retinal nerve fiber layer superior quadrant measurement and hospitalization (r=0.380, p=0.039). Conclusion: Our results revealed that the patients' central macular thickness, mean macular thickness, and mean macular volume values were thinner. Increase in the retinal nerve fiber layer thickness superior quadrant thickness and total value was also observed. Further studies with larger sampling groups that evaluate neuroimaging findings should be conducted.

RESUMO Objetivo: O objetivo foi investigar foi, os achados da tomografia de coerência óptica em pacientes com transtorno do uso de opiáceos, comparando-os com controles saudáveis. Métodos: O estudo incluiu 30 pacientes com transtorno do uso de opiáceos e 30 controles. Os exames biomicroscópicos detalhados de todos os participantes, acuidade visual, pressão intraocular e ambos os exames oculares foram avaliados com tomografia de coerência óptica. Um total de 120 olhos foram avaliados usando tomografia de coerência óptica, e a espessura macular central, espessura macular média, volume macular médio e a espessura da camada de fibra nervosa da retina dos participantes foram medidos. Além disso, todos os participantes preencheram o Formulário de Dados Demográficos e a Escala de Impulsividade Barratt (BIS-11). Resultados: Quando os achados de tomografia de coerência óptica foram examinados, espessura macular central, espessura macular média e volume macular médio eram mais finos de acordo com controles saudáveis em ambos os olhos em pacientes com transtorno do uso de opiáceos (p<0,01 em todas as medições em ambos os olhos). Da mesma forma, os valores totais do quadrante superior e espessura da camada de fibra nervosa da retina estavam mais em níveis estatisticamente significativos em ambos os olhos em comparação com o grupo controle (p=0,007, p=0,002; p=0,049, p=0,007, no olho direito e esquerdo, respectivamente). Estar internado em hospital e apenas a medida do quadrante superior da espessura da camada de fibra nervosa da retina do olho esquerdo associou-se positivamente (r=0,380, p=0,039). Conclusão: Em nossos resultados, descobrimos que os valores de espessura macular central, espessura macular média e volume macular médio dos pacientes eram mais finos. Verificamos também espessamento no quadrante superior e valor total da espessura da camada de fibra nervosa da retina. Nosso estudo deve ser apoiado por novos estudos com grupos de amostragem maiores, nos quais os achados de neuroimagem são avaliados.

Factors associated with all-cause mortality at 90 days in hospitalized adult patients who received parenteral nutrition / Factores asociados a mortalidad a los 90 días en pacientes adultos hospitalizados que recibieron nutrición parenteral

Objective: this study aimed to assess the main factors related to mortality in a cohort of hospitalized adult patients who required parenteral nutrition (PN) considering their characteristics, type of admission, procedures, nutritional data, and adverse events. Methods: a retrospective study was performed in a 400-bed university hospital. All adult inpatients that had received ≥ 4 days as first course of PN within 24 months were included. Patients with long-term (> 90 days) or home PN were excluded. The main variable was all-cause mortality at 90 days after the end of PN. Initial independent variables were anthropometric and demographic data, admission characteristics, severity, comorbidity, surgical/medical procedures, baseline biochemical parameters, nutritional risk, and other nutritional data, medications, and adverse events during PN. A Cox proportional hazards regression model was planned to analyze time-to-event data. Results: a total of 634 patients entered the study and 140 (22.1 %) died. Patients were mainly: surgical 471 (74.3 %), male 393 (62.0 %), and age 69.0 (67.8-70.1) years old. The survival time for the entire cohort was 74.0 (95 % CI: 71.6-76.6) days. The final model included 14 variables, with severity and comorbidity being the main ones, but including also anastomotic suture dehiscence, sepsis during PN, days with hyperglycemic events, use of potent opioids, failed attempts at enteral nutrition, and, as a protective one, energy provided in PN. Conclusions: the factors related to mortality in hospitalized adult patients who required PN were mainly severity and comorbidities, but several other important factors were also relevant and could be modified to maximize outcomes in these patients (AU)

Objetivo: valorar los factores relacionados con la mortalidad en una cohorte de pacientes adultos hospitalizados que recibieron nutrición parenteral (NP) atendiendo a sus características, procedimientos, parámetros nutricionales y complicaciones. Métodos estudio retrospectivo realizado en un hospital universitario de 400 camas. Se incluyeron todos los pacientes adultos que recibieron ≥ 4 días de NP en un periodo de 24 meses. Se excluyeron los pacientes con NP de largo plazo (> 90 días) o NP domiciliaria. La variable principal fue la mortalidad por cualquier causa en los 90 días posteriores al fin de la NP. Las variables independientes iniciales fueron los datos antropométricos y demográficos, el tipo de ingreso, la gravedad, la comorbilidad, los procedimientos médicos/quirúrgicos, los parámetros bioquímicos, el riesgo nutricional, otros parámetros nutricionales, las medicaciones y los eventos adversos durante la NP. Se realizó un análisis de supervivencia por el modelo de los riesgos proporcionales de Cox. esultados en total, 634 pacientes entraron en el estudio, de los cuales 140 (22,1 %) murieron. Los pacientes fueron principalmente: quirúrgicos 471 (74,3 %), hombres 393 (62,0 %) y de 69,0 (67,8-70,1) años de edad. La supervivencia de toda la cohorte fue de 74,0 (IC 95 %: 71,6-76,6) días. El modelo final incluyó 14 variables. La gravedad y la comorbilidad fueron las principales, pero también resultaron incluidas la dehiscencia de la sutura, la sepsis, los días con hiperglucemia, los intentos fallidos de nutrición enteral, el uso de opiáceos potentes y, como protector, la energía administrada en la NP. Conclusión:los factores relacionados con la mortalidad en estos pacientes con NP fueron principalmente la gravedad y la comorbilidad, pero otros factores también fueron relevantes y podrían ser modificados para maximizar los resultados en salud (AU)

Factors associated with all-cause mortality at 90 days in hospitalized adult patients who received parenteral nutrition.

Introduction: Objective: this study aimed to assess the main factors related to mortality in a cohort of hospitalized adult patients who required parenteral nutrition (PN) considering their characteristics, type of admission, procedures, nutritional data, and adverse events. Methods: a retrospective study was performed in a 400-bed university hospital. All adult inpatients that had received ≥ 4 days as first course of PN within 24 months were included. Patients with long-term (> 90 days) or home PN were excluded. The main variable was all-cause mortality at 90 days after the end of PN. Initial independent variables were anthropometric and demographic data, admission characteristics, severity, comorbidity, surgical/medical procedures, baseline biochemical parameters, nutritional risk, and other nutritional data, medications, and adverse events during PN. A Cox proportional hazards regression model was planned to analyze time-to-event data. Results: a total of 634 patients entered the study and 140 (22.1 %) died. Patients were mainly: surgical 471 (74.3 %), male 393 (62.0 %), and age 69.0 (67.8-70.1) years old. The survival time for the entire cohort was 74.0 (95 % CI: 71.6-76.6) days. The final model included 14 variables, with severity and comorbidity being the main ones, but including also anastomotic suture dehiscence, sepsis during PN, days with hyperglycemic events, use of potent opioids, failed attempts at enteral nutrition, and, as a protective one, energy provided in PN. Conclusions: the factors related to mortality in hospitalized adult patients who required PN were mainly severity and comorbidities, but several other important factors were also relevant and could be modified to maximize outcomes in these patients.

Introducción: Objetivo: valorar los factores relacionados con la mortalidad en una cohorte de pacientes adultos hospitalizados que recibieron nutrición parenteral (NP) atendiendo a sus características, procedimientos, parámetros nutricionales y complicaciones. Métodos: estudio retrospectivo realizado en un hospital universitario de 400 camas. Se incluyeron todos los pacientes adultos que recibieron ≥ 4 días de NP en un periodo de 24 meses. Se excluyeron los pacientes con NP de largo plazo (> 90 días) o NP domiciliaria. La variable principal fue la mortalidad por cualquier causa en los 90 días posteriores al fin de la NP. Las variables independientes iniciales fueron los datos antropométricos y demográficos, el tipo de ingreso, la gravedad, la comorbilidad, los procedimientos médicos/quirúrgicos, los parámetros bioquímicos, el riesgo nutricional, otros parámetros nutricionales, las medicaciones y los eventos adversos durante la NP. Se realizó un análisis de supervivencia por el modelo de los riesgos proporcionales de Cox. Resultados: en total, 634 pacientes entraron en el estudio, de los cuales 140 (22,1 %) murieron. Los pacientes fueron principalmente: quirúrgicos 471 (74,3 %), hombres 393 (62,0 %) y de 69,0 (67,8-70,1) años de edad. La supervivencia de toda la cohorte fue de 74,0 (IC 95 %: 71,6-76,6) días. El modelo final incluyó 14 variables. La gravedad y la comorbilidad fueron las principales, pero también resultaron incluidas la dehiscencia de la sutura, la sepsis, los días con hiperglucemia, los intentos fallidos de nutrición enteral, el uso de opiáceos potentes y, como protector, la energía administrada en la NP. Conclusión: los factores relacionados con la mortalidad en estos pacientes con NP fueron principalmente la gravedad y la comorbilidad, pero otros factores también fueron relevantes y podrían ser modificados para maximizar los resultados en salud.

Actualización de la Guía Española de la EPOC (GesEPOC): comorbilidades, automanejo y cuidados paliativos / Spanish COPD Guideline (GesEPOC) Update: Comorbidities, Self-Management and Palliative Care

Los modelos de atención sanitaria actuales descritos en GesEPOC indican la mejor manera de hacer un diagnóstico correcto, la categorización de los pacientes, la adecuada selección de la estrategia terapéutica y el manejo y la prevención de las agudizaciones. Además, en la EPOC concurren diversos aspectos que resultan cruciales en una aproximación integrada de la atención sanitaria a estos pacientes. La evaluación de las comorbilidades en el paciente con EPOC representa un reto asistencial. Dentro de una valoración integral debe estudiarse la presencia de comorbilidades que tengan relación con la presentación clínica, con alguna técnica diagnóstica o con algunos tratamientos relacionados con la EPOC. Asimismo, son necesarias intervenciones en hábitos de vida saludables, la adhesión a tratamientos complejos, desarrollar capacidades para poder reconocer los signos y síntomas de la exacerbación, saber qué hacer para prevenirlos y tratarlos enmarcados en un plan de automanejo. Finalmente, los cuidados paliativos constituyen uno de los pilares en el tratamiento integral del paciente con EPOC, con los que se buscan prevenir o tratar los síntomas de una enfermedad, los efectos secundarios del tratamiento, y los problemas físicos, psicológicos y sociales de los pacientes y sus cuidadores. Por tanto, el objetivo principal de estos cuidados paliativos no es prolongar la esperanza de vida, sino mejorar su calidad. En este capítulo de GesEPOC 2021 se presenta una actualización sobre las comorbilidades más importantes, las estrategias de automanejo y los cuidados paliativos en la EPOC, y se incluye una recomendación sobre el uso de opiáceos para el tratamiento de la disnea refractaria en la EPOC. (AU)

The current health care models described in GesEPOC indicate the best way to make a correct diagnosis, the categorization of patients, the appropriate selection of the therapeutic strategy and the management and prevention of exacerbations. In addition, COPD involves several aspects that are crucial in an integrated approach to the health care of these patients. The evaluation of comorbidities in COPD patients represents a healthcare challenge. As part of a comprehensive assessment, the presence of comorbidities related to the clinical presentation, to some diagnostic technique or to some COPD-related treatments should be studied. Likewise, interventions on healthy lifestyle habits, adherence to complex treatments, developing skills to recognize the signs and symptoms of exacerbation, knowing what to do to prevent them and treat them within the framework of a self-management plan are also necessary. Finally, palliative care is one of the pillars in the comprehensive treatment of the COPD patient, seeking to prevent or treat the symptoms of a disease, the side effects of treatment, and the physical, psychological and social problems of patients and their caregivers. Therefore, the main objective of this palliative care is not to prolong life expectancy, but to improve its quality. This chapter of GesEPOC 2021 presents an update on the most important comorbidities, self-management strategies, and palliative care in COPD, and includes a recommendation on the use of opioids for the treatment of refractory dyspnea in COPD. (AU)

[Translated article] Spanish COPD Guideline (GesEPOC) Update: Comorbidities, Self-Management and Palliative Care / Actualización de la Guía Española de la EPOC (GesEPOC): comorbilidades, automanejo y cuidados paliativos

The current health care models described in GesEPOC indicate the best way to make a correct diagnosis, the categorization of patients, the appropriate selection of the therapeutic strategy and the management and prevention of exacerbations. In addition, COPD involves several aspects that are crucial in an integrated approach to the health care of these patients. The evaluation of comorbidities in COPD patients represents a healthcare challenge. As part of a comprehensive assessment, the presence of comorbidities related to the clinical presentation, to some diagnostic technique or to some COPD-related treatments should be studied. Likewise, interventions on healthy lifestyle habits, adherence to complex treatments, developing skills to recognize the signs and symptoms of exacerbation, knowing what to do to prevent them and treat them within the framework of a self-management plan are also necessary. Finally, palliative care is one of the pillars in the comprehensive treatment of the COPD patient, seeking to prevent or treat the symptoms of a disease, the side effects of treatment, and the physical, psychological and social problems of patients and their caregivers. Therefore, the main objective of this palliative care is not to prolong life expectancy, but to improve its quality. This chapter of GesEPOC 2021 presents an update on the most important comorbidities, self-management strategies, and palliative care in COPD, and includes a recommendation on the use of opioids for the treatment of refractory dyspnea in COPD. (AU)

Los modelos de atención sanitaria actuales descritos en GesEPOC indican la mejor manera de hacer un diagnóstico correcto, la categorización de los pacientes, la adecuada selección de la estrategia terapéutica y el manejo y la prevención de las agudizaciones. Además, en la EPOC concurren diversos aspectos que resultan cruciales en una aproximación integrada de la atención sanitaria a estos pacientes. La evaluación de las comorbilidades en el paciente con EPOC representa un reto asistencial. Dentro de una valoración integral debe estudiarse la presencia de comorbilidades que tengan relación con la presentación clínica, con alguna técnica diagnóstica o con algunos tratamientos relacionados con la EPOC. Asimismo, son necesarias intervenciones en hábitos de vida saludables, la adhesión a tratamientos complejos, desarrollar capacidades para poder reconocer los signos y síntomas de la exacerbación, saber qué hacer para prevenirlos y tratarlos enmarcados en un plan de automanejo. Finalmente, los cuidados paliativos constituyen uno de los pilares en el tratamiento integral del paciente con EPOC, con los que se buscan prevenir o tratar los síntomas de una enfermedad, los efectos secundarios del tratamiento, y los problemas físicos, psicológicos y sociales de los pacientes y sus cuidadores. Por tanto, el objetivo principal de estos cuidados paliativos no es prolongar la esperanza de vida, sino mejorar su calidad. En este capítulo de GesEPOC 2021 se presenta una actualización sobre las comorbilidades más importantes, las estrategias de automanejo y los cuidados paliativos en la EPOC, y se incluye una recomendación sobre el uso de opiáceos para el tratamiento de la disnea refractaria en la EPOC. (AU)

Influencia de los trastornos psiquiátricos y la terapia de sustitución con opiáceos en el tratamiento del virus de la hepatitis c con antivirales de acción directa en usuarios de drogas por vía parenteral / Influence of psychiatric disorders and opioid substitution therapy on hepatitis C treatment with direct-acting antivirals in people who inject drugs

Introducción: La efectividad del tratamiento del virus de la hepatitis C (VHC) parece ser menor en usuarios de drogas por vía parenteral (UDVP). Analizamos la influencia de diversos factores como los trastornos psiquiátricos y la terapia de sustitución con opiáceos (TSO) en el tratamiento con antivirales de acción directa (AAD) de este colectivo.Pacientes y métodos: Trescientos treinta y dos pacientes UDVP fueron tratados con AAD en 12 hospitales de España entre 2004 y 2020. Se catalogaron, si se disponía del dato, en consumidores recientes y pasados (según si el último consumo fue en los últimos 3 años) y se recogieron diversas variables, evaluándose la efectividad del tratamiento según la carga viral 12 semanas tras la finalización del tratamiento con el parámetro «respuesta viral sostenida» (RVS12).Resultados: El 23,4% eran consumidores recientes y el 27,7% estaban en TSO. El 41,5% presentaban algún diagnóstico de enfermedad psiquiátrica. La RVS12 fue del 84,04%, ascendiendo al 96,21% al excluir del análisis a los pacientes que perdieron el seguimiento (12,7%). La RVS12 fue significativamente inferior debido a un aumento de la pérdida de seguimiento en consumidores recientes, aquellos en TSO, los que habían estado en prisión los últimos 5 años y pacientes naïve, así como en el trastorno de ansiedad generalizada y consumidores de benzodiacepinas.Conclusiones: La efectividad del tratamiento del VHC con AAD en UDVP es similar a la población general si se consigue un adecuado seguimiento. Es importante realizar un seguimiento más estrecho en pacientes en TSO, consumidores recientes y aquellos con enfermedad psiquiátrica.(AU)

Introduction: The effectiveness of the hepatitis C virus (HCV) treatment seems to be lower in people who inject drugs (PWID). We analyze the influence of various factors as psychiatric disorders and opioid substitution therapy (OST) on the treatment with direct-acting antivirals (DAA) in this collective.Patients and methods: Three hundred thirty-two PWID patients were treated with DAA in 12 Spanish hospitals between 2004 and 2020. They were catalogued in recent and former consumers (if the last consumption was in the last 3 years) and several variables were included, evaluating the effectiveness of the treatment according to the viral load 12 weeks after the end of the treatment with the parameter «sustained viral response» (SVR12).Results: 23.4% were recent consumers and 27.7% were on OST. The 41.5% had any diagnosis of psychiatric disorder. SVR12 was 84.04%, ascending to 96.21% when excluded from the analyses the patients lost to follow-up (12.7%). SVR12 was lower due to an increase in the loss to follow-up in recent consumers and other factors like OST, being in prison the last 5 years, naïve patients, generalized anxiety disorder and benzodiazepine consumption.Conclusions: The effectiveness of the HCV treatment with DAA in PWID is similar than in general population in patients whit an appropriate follow-up. It is important to maintain a closer follow-up in patients on OST, recent consumers and those with psychiatric disorders.(AU)

Spanish COPD Guideline (GesEPOC) Update: Comorbidities, Self-Management and Palliative Care. / Actualización de la Guía Española de la EPOC (GesEPOC): comorbilidades, automanejo y cuidados paliativos.

The current health care models described in GesEPOC indicate the best way to make a correct diagnosis, the categorization of patients, the appropriate selection of the therapeutic strategy and the management and prevention of exacerbations. In addition, COPD involves several aspects that are crucial in an integrated approach to the health care of these patients. The evaluation of comorbidities in COPD patients represents a healthcare challenge. As part of a comprehensive assessment, the presence of comorbidities related to the clinical presentation, to some diagnostic technique or to some COPD-related treatments should be studied. Likewise, interventions on healthy lifestyle habits, adherence to complex treatments, developing skills to recognize the signs and symptoms of exacerbation, knowing what to do to prevent them and treat them within the framework of a self-management plan are also necessary. Finally, palliative care is one of the pillars in the comprehensive treatment of the COPD patient, seeking to prevent or treat the symptoms of a disease, the side effects of treatment, and the physical, psychological and social problems of patients and their caregivers. Therefore, the main objective of this palliative care is not to prolong life expectancy, but to improve its quality. This chapter of GesEPOC 2021 presents an update on the most important comorbidities, self-management strategies, and palliative care in COPD, and includes a recommendation on the use of opioids for the treatment of refractory dyspnea in COPD.

Influence of psychiatric disorders and opioid substitution therapy on hepatitis C treatment with direct-acting antivirals in people who inject drugs. / Influencia de los trastornos psiquiátricos y la terapia de sustitución con opiáceos en el tratamiento del virus de la hepatitis c con antivirales de acción directa en usuarios de drogas por vía parenteral.

INTRODUCTION: The effectiveness of the hepatitis C virus (HCV) treatment seems to be lower in people who inject drugs (PWID). We analyze the influence of various factors as psychiatric disorders and opioid substitution therapy (OST) on the treatment with direct-acting antivirals (DAA) in this collective. PATIENTS AND METHODS: Three hundred thirty-two PWID patients were treated with DAA in 12 Spanish hospitals between 2004 and 2020. They were catalogued in recent and former consumers (if the last consumption was in the last 3 years) and several variables were included, evaluating the effectiveness of the treatment according to the viral load 12 weeks after the end of the treatment with the parameter «sustained viral response¼ (SVR12). RESULTS: 23.4% were recent consumers and 27.7% were on OST. The 41.5% had any diagnosis of psychiatric disorder. SVR12 was 84.04%, ascending to 96.21% when excluded from the analyses the patients lost to follow-up (12.7%). SVR12 was lower due to an increase in the loss to follow-up in recent consumers and other factors like OST, being in prison the last 5 years, naïve patients, generalized anxiety disorder and benzodiazepine consumption. CONCLUSIONS: The effectiveness of the HCV treatment with DAA in PWID is similar than in general population in patients whit an appropriate follow-up. It is important to maintain a closer follow-up in patients on OST, recent consumers and those with psychiatric disorders.

Riesgo de la prescripción de opioides para el manejo del dolor / Risk of Opioid Prescriptions for Management of Pain / Risco de prescrição de opioides para o tratamento da dor

actualmente existe una intensa prescripción de opioides para el manejo de todo tipo de dolor a nivel clínico, razón por la cual es importante considerar los posibles daños derivados de esta actividad, tales como tolerancia, adicción, dependencia y sobredosis. La medicación de opiáceos o sus derivados de manera irracional para el manejo del dolor agudo o crónico puede ser la puerta de entrada a las drogodependencias. Muchos adictos a opiáceos informaron haber estado expuestos por primera vez a los opioides a través de una prescripción médica para el tratamiento del dolor. Por ello, es importante evaluar por parte de los profesionales de la salud el uso a largo plazo de estos medicamentos para el manejo del dolor, porque estudios han evidenciado una relación entre el uso clínico y la dependencia de estos, sobre todo en adolescentes y adultos jóvenes sin experiencia en opiáceos que fueron sometidos a procedimientos quirúrgicos y dentales.

Currently, opioids for managing all types of pain are increasingly prescribed at the clinical level, which is why it is important to consider the potential harms derived from this practice, such as tolerance, addiction, dependence, and overdose. Irrational medication of opioids or opioid derivatives for acute or chronic pain management can be the gateway to drug dependence. Many opioid addicts reported first being exposed to opioids after receiving a physician's prescription for pain management. Therefore, health professionals need to evaluate the long-term use of these medications to manage pain because studies have shown a relationship between clinical use and opioid dependence, especially in adolescents and young adults who had never received opioid therapy and who underwent surgical and dental procedures

Atualmente existe uma intensa prescrição de opioides para o manejo de todos os tipos de dor em nível clínico, por isso é importante considerar os possíveis danos decorrentes dessa atividade, como tolerância, adição, dependência e overdose. A medicação de opiáceos ou seus derivados de forma irracional para o manejo da dor aguda ou crônica pode ser a porta de entrada para a adição a drogas. Muitos dependentes de opioides relataram ter sido expostos a opioides pela primeira vez por meio de uma receita médica para o tratamento da dor. Por esse motivo, é importante que os profissionais de saúde avaliem o uso prolongado desses medicamentos para o manejo da dor, pois estudos têm mostrado relação entre o uso clínico e a dependência dos mesmos, principalmente em adolescentes e adultos jovens sem experiência com opioides que foram submetidos a procedimentos cirúrgicos e odontológicos

Estudio comparativo de las visitas a urgencias por intoxicaciones por opiáceos en dos periodos / Comparative study of visits to Hospital Emergency Department for opioid overdose in two periods

Objetivo: El uso de fármacos opioides ha aumentado en las últimas décadas, así como las intoxicaciones relacionadas con su uso. El objetivo de esteestudio es evaluar el número de visitas a urgencias en un hospital universitariopor intoxicaciones por opiáceos entre dos periodos y analizar las posiblesdiferencias de las características de los pacientes, perfil de prescripción y eltratamiento de dicha intoxicación.Método: Estudio observacional, retrospectivo de las visitas debidas aintoxicaciones por fármacos opiáceos en dos periodos: 2009-2014 y2018-2020.Resultados: Se incluyeron 47 casos de intoxicaciones, 20 en el primer periodo (3,3 casos/año) y 27 en el segundo (9 casos/año). Seobservó una disminución en la edad de los pacientes (81,1 versus 74,0;p = 0,044) y un incremento de tratamientos debidos a dolor traumatológico agudo a expensas de menos tratamientos de dolor crónico(p = 0,002). No hubo diferencias en el opiáceo implicado. Con respectoa la clínica, se observó una disminución en los síndromes confusionales(p = 0,026) y un incremento de fallecimientos.Conclusiones: Las visitas a urgencias por intoxicaciones a fármacosopiáceos han aumentado en los últimos años, así como la mortalidadasociada. El perfil de los pacientes implicados ha variado, incrementándose el tratamiento de dolor traumatológico agudo. (AU)

Objective: The last few years have seen an increase in the use of opioidanalgesics and in the incidence of opioid overdoses. The objective of thisstudy was to evaluate the number of overdose-related visits to a universityhospital emergency department at two different periods of time to analyzepotential differences in terms of patient characteristics, prescription profile,and treatment.Method: This is a retrospective observational study of opioid overdoserelated visits in two periods of time: 2009-2014 and 2018-2020.Results: The study included 47 cases of opioid overdoses: 20 during thefirst period (3.3 cases/year) and 27 during the second (9 cases/year). Acomparison between the two period showed a decrease in the patients’age (81.1 vs 74.0; p = 0.044) and an increase in the number of acutetrauma-derived pain treatments at the expense of chronic pain treatments(p = 0.002). No differences were observed in the opioids involved. Asregards symptoms, there was a decrease in the incidence of confusionalsyndromes (p = 0.026) and an increase in deaths.Conclusions: Emergency room visits for opioid overdoses have increased in recent years, as has the mortality associated to them. A changehas also been observed in the profile of affected patients, with a highernumber of cases where pain is derived from acute trauma. (AU)

Revisión de mezclas binarias, ternariasy cuaternarias para inducción y mantenimiento de anestesia libre de opiáceos / Review of binary, ternary and quaternary mixtures for induction and maintenance of opioid free anesthesia

Objetivo: Describir y estructurar la información actual disponible sobremezclas binarias, ternarias y/o cuaternarias empleadas en una “anestesialibre de opiáceos”, así como su estabilidad fisicoquímica, para facilitar sucorrecta administración, optimizar su uso y prevenir posibles problemasde efectividad o seguridad.Método: Revisión sistemática de la literatura sobre anestesia libre deopiáceos en PubMed/Medline, Trissel, Micromedex, Lexicomp, AHFS DrugInformation, Extended Stability for Parenteral Drugs y Stabilis Web. Artículos publicados en inglés o español hasta mayo de 2020 y con acceso atexto completo. Se emplearon los términos MeSH: “Drug Incompatibility”AND “Opioid Free Anesthesia” AND “Administration, Intravenous” AND“Dexmedetomidine” AND “Lidocaine” AND “Ketamine” AND “SulphateMagnesium” OR “Infusions, Intravenous”. Se realizó una primera búsquedaen PubMed/Medline incluyendo casos clínicos de anestesia general tipoanestesia libre de opiáceos. Los resultados obtenidos se estructuraron enuna base de datos. La segunda búsqueda fue sobre incompatibilidadesde las mezclas intravenosas. Se recogieron medicamentos compatibles/incompatibles; concentraciones de referencia; tiempo de estabilidad a temperatura ambiente (23 ± 2 °C) y en refrigeración (4 ± 2 °C); tipo de administración recomendada y resultados y conclusiones relevantes. Se crearon dos tablas bidimensionales de la compatibilidad de cada combinación defármacos para la administración en Y o en mezcla en una sola solución.Resultados: Se identificaron 780 artículos; se accedió al texto completo de 203. Se recogieron de forma cronológica los 4.762 casos tratados en 32 diferentes publicaciones con protocolos de anestesia librede opiáceos. El uso de dos fármacos fue la asociación más frecuente(42,4%). Los fármacos más empleados fueron dexmedetomidina (25 trabajos), clorhidrato de ketamina (25 trabajos) y lidocaína (14 trabajos). (AU)

Objective: To describe and organize the current information availableon binary, ternary and/or quaternary mixtures used in opioid-free anesthesia (OFA), as well as their physicochemical stability, in order to facilitate itscorrect administration, optimize its use, and prevent potential effectivenessand safety issues.Method: A systematic review of the literature on OFA was conductedin PubMed/Medline, Trissel, Micromedex, Lexicomp, www.ahfsdruginformation.com, ASHP’s Extended Stability for Parenteral Drugs, and www.stabilis.org. Only articles published in English or Spanish until May 2020and with access to full text were considered. MeSH terms used included:“drug incompatibility” AND “opioid-free anesthesia” AND “administration,intravenous” AND “dexmedetomidine” AND “lidocaine” AND “ketamine”AND “magnesium sulphate” OR “infusions, intravenous. A first search wascarried out in PubMed/Medline that included OFA clinical cases. Theresults obtained were collected in a database. A second search wascarried out on the incompatibilities of intravenous mixtures. Informationwas compiled on mutually-compatible/incompatible drugs, reference concentrations, stability time at room temperature (23 ± 2 °C) and under refrigeration (4 ± 2 ºC), type of administration recommended, and relevantresults and conclusions. Two two-dimensional tables on the compatibility of each drug combination were created for administration as Y-site infusionor as a mixture in a single solution. (AU)

Cannabis for medical and scientific purposes: the Colombian landscape / Panorama del cannabis con fines médicos y científicos en Colombia

Abstract The Colombian government, through Law 1787 of 2016, has created a regulatory framework that allows its citizens to have a safe and informed access to cannabis and its derivatives for medical and scientific purposes. Our country joins others in their efforts to legalize cannabis-derived substances for therapeutic purposes, as many jurisdictions have recognized the potential these products have in the treatment of certain medical conditions. This paper describes the current medical cannabis outlook in Colombia, compares the different medical cannabis supply systems in other parts of the world, summarizes the evidence related to the potential therapeutic benefits and potential risks of using cannabis for medical purposes.

Resumen Mediante la Ley 1787 de 2016, el Gobierno colombiano creó el marco regulatorio que permite el acceso seguro e informado al uso médico y científico del cannabis y sus derivados en nuestro territorio. Este movimiento hacia la legalización de sustancias derivadas de cannabis con fines terapéuticos se suma a otros instaurados en otros países que han reconocido el posible potencial que tienen estos productos en el tratamiento de ciertas condiciones clínicas. Este artículo describe la situación actual del cannabis medicinal en Colombia, compara los diferentes sistemas de provisión de cannabis con fines médicos en otras jurisdicciones, resume la evidencia alrededor de su utilización con fines médicos que justifica la legalización, y los potenciales riesgos que existen con el uso del cannabis.

Consumo de fármacos opiáceos en la ciudad de Madrid: Factores sanitarios y sociodemográficos asociados / Opiate drug use in the city of Madrid: Associated health and sociodemographic factors

El consumo de analgésicos opiáceos ha provocado una situación deemergencia sanitaria y social en Estados Unidos. En España, segúndatos oficiales, la prescripción de estos fármacos ha experimentadoun espectacular ascenso en la última década. Este estudio explora laprevalencia del uso de estos fármacos y las características sanitarias ysociodemográficas de sus consumidores en la ciudad de Madrid. Serealizó una encuesta telefónica aplicando un muestreo estratificadoy aleatorizado, en la que se preguntó por el uso de estos fármacos ysi fueron médicamente prescritos o no. La muestra estuvo compuestapor n= 8.845 sujetos de edades entre 15 y 98 años. Un 16,0% declara haber usado estos fármacos en el último año y un 9,1 los tomaen las dos últimas semanas. El consumo es más frecuente en mujeres, clase social baja y menor nivel de estudios. El grupo más joven(15-29 años) ya lo usa en el 12,5%. Quienes usan opioides refierenpeor salud percibida, menor calidad de vida, más problemas de saludmental, más soledad no deseada, más uso de otros psicofármacos, másfrecuente uso diario de tabaco y menos consumo problemático dealcohol. Un 10% de quienes los usan lo hacen sin prescripción médica. Combinando estos datos con los de prescripción ofrecidos por elMinisterio de Sanidad, resulta necesario prestar atención a un problema que puede hacerse patente en los próximos años, aconsejando laadopción de medidas urgentes para atajarlo antes de que aproxime lasituación española a la ya bien conocida en otros países. (AU)

The use of opiate analgesics has led to a health and social emergencyin the United States. In Spain, according to official data, the prescription of these drugs has risen dramatically in the last decade. This studyexplores the prevalence of the use of these drugs and the health andsocio-demographic characteristics of their consumers in the city ofMadrid. A telephone survey was carried on a stratified, randomisedsample, asking about the use of these drugs and whether or not theywere medically prescribed. The sample consisted of n=8,845 subjectsaged between 15 and 98 years. Sixteen percent stated that they hadused these drugs in the last year and 9.1% had taken them in the lasttwo weeks. Consumption was more frequent among women, lower social class and lower level of education. Among the youngest group (15-29 years old) 12.5% had already used it. Those who use opioids reportworse perceived health, lower quality of life, more mental health problems, more loneliness, more use of other psychoactive drugs, morefrequent daily use of tobacco and less problematic consumption ofalcohol. Ten percent of those who use them do so without a doctor’sprescription. Combining these data with the prescription data offeredby the Ministry of Health, it is necessary to pay attention to a problem that may become apparent in the coming years, and the adoptionof urgent measures to tackle it before it brings the Spanish situationcloser to that already well known in countries of our socio-politicalenvironment is advised (AU)